BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nair R, Neelapu SS. The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol. 2018;31:293-298. [PMID: 30213399 DOI: 10.1016/j.beha.2018.07.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Yu F, Wang X, Shi H, Jiang M, Xu J, Sun M, Xu Q, Addai FP, Shi H, Gu J, Zhou Y, Liu L. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer. Tumori 2021;107:341-52. [PMID: 32988314 DOI: 10.1177/0300891620960223] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tao L, Farooq MA, Gao Y, Zhang L, Niu C, Ajmal I, Zhou Y, He C, Zhao G, Yao J, Liu M, Jiang W. CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19+HLA-C1- Malignant B Cells While Sparing CD19+HLA-C1+ Healthy B Cells. Cancers (Basel) 2020;12:E2612. [PMID: 32933182 DOI: 10.3390/cancers12092612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Yin X, Xu A, Fan F, Huang Z, Cheng Q, Zhang L, Sun C, Hu Y. Incidence and Mortality Trends and Risk Prediction Nomogram for Extranodal Diffuse Large B-Cell Lymphoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. Front Oncol 2019;9:1198. [PMID: 31781500 DOI: 10.3389/fonc.2019.01198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Dumont M, Battistella M, Ram-Wolff C, Bagot M, de Masson A. Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives. Cancers (Basel) 2020;12:E1497. [PMID: 32521744 DOI: 10.3390/cancers12061497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ding S, Mao X, Cao Y, Wang N, Xu H, Zhou J. Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas. Target Oncol 2020;15:365-75. [PMID: 32495161 DOI: 10.1007/s11523-020-00729-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Kallam A, Vose JM. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19:751-757. [PMID: 31648957 DOI: 10.1016/j.clml.2019.09.598] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
7 Shi R, Lu T, Ku G, Ding H, Saito T, Gibiansky L, Agarwal P, Li X, Jin JY, Girish S, Miles D, Li C, Lu D. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2020;86:347-59. [PMID: 32770353 DOI: 10.1007/s00280-020-04119-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Crisci S, Di Francia R, Mele S, Vitale P, Ronga G, De Filippi R, Berretta M, Rossi P, Pinto A. Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. Front Oncol 2019;9:443. [PMID: 31214498 DOI: 10.3389/fonc.2019.00443] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
9 Menter T, Tzankov A, Dirnhofer S. The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors. Hematol Oncol 2021;39:3-10. [PMID: 33105031 DOI: 10.1002/hon.2821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wan Z, Sun R, Moharil P, Chen J, Liu Y, Song X, Ao Q. Research advances in nanomedicine, immunotherapy, and combination therapy for leukemia. J Leukoc Biol 2021;109:425-36. [PMID: 33259068 DOI: 10.1002/JLB.5MR0620-063RR] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Herrera L, Santos S, Vesga MA, Anguita J, Martin-Ruiz I, Carrascosa T, Juan M, Eguizabal C. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci Rep 2019;9:18729. [PMID: 31822751 DOI: 10.1038/s41598-019-55239-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
12 Levin A, Shah NN. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. Am J Hematol 2019;94:S18-23. [PMID: 30652353 DOI: 10.1002/ajh.25403] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
13 Habib R, Nagrial A, Micklethwaite K, Gowrishankar K. Chimeric Antigen Receptors for the Tumour Microenvironment. Adv Exp Med Biol 2020;1263:117-43. [PMID: 32588326 DOI: 10.1007/978-3-030-44518-8_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Strati P, Neelapu SS. Chimeric Antigen Receptor–Engineered T Cell Therapy in Lymphoma. Curr Oncol Rep 2019;21. [DOI: 10.1007/s11912-019-0789-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
15 Chen PH, Lipschitz M, Weirather JL, Jacobson C, Armand P, Wright K, Hodi FS, Roberts ZJ, Sievers SA, Rossi J, Bot A, Go W, Rodig SJ. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight 2020;5:134612. [PMID: 32484797 DOI: 10.1172/jci.insight.134612] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
16 Imber BS, Sadelain M, DeSelm C, Batlevi C, Brentjens RJ, Dahi PB, Giralt S, Park JH, Sauter C, Scordo M, Shah G, Perales MA, Palomba ML, Yahalom J. Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. Br J Haematol 2020;190:45-51. [PMID: 32135029 DOI: 10.1111/bjh.16541] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
17 Strati P, Ahmed MA, Fowler NH, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS. Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 2020;105:1907-13. [PMID: 31601688 DOI: 10.3324/haematol.2019.230649] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]